NCT00425737View on ClinicalTrials.gov

Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2001

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Rotarix

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00425737 - Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants | Biotech Hunter | Biotech Hunter